Message #43 From:
NewsBot Date: December 22, 2005 02:00:00 AM
SWME News Swiss Medica Confirms Record Net Revenues in Excess of US$2 Million in Fourth Quarter
TORONTO--(BUSINESS WIRE)--Dec. 22, 2005--Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that net revenues for the fourth quarter ending December 31, 2005 will be in excess of US$2 million. This revenue level is in line with the updated guidance that was given in the press release dated October 19, 2005. Fiscal 2005 revenues will be in excess of US$6.3 million.
Swiss Medica will announce final fourth quarter net revenues and other fourth quarter operating highlights by January 13th, 2006. Full fourth quarter and fiscal 2005 audited financial statements will be included in the Company's 10-K, which will be filed with the U.S. Securities and Exchange Commission by March 31, 2006.
Swiss Medica CEO Raghu Kilambi commented, "We are pleased with our continued growth in the fourth quarter and growing acceptance for our three products in North America. We are confident that 2006 will bring further growth and expansion into new channels and markets."
About Swiss Medica, Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.
Swiss Medica also manufactures PMS Escape(R) which holds US Patent #'s 5760014 and 5612320. PMS Escape(R) is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
